Our research interests include:

Rational design and optimization of nano platforms for drug delivery purposes in various disease models such as solid tumors, regenerative medicine, pulmonary disease and rare genetic disease. We have tailored-designed various platforms to deliver a variety of payloads, including cancer drugs, small molecule inhibitors, antibiotics, nucleic acids (e.g. siRNA, plasmid and mRNA), and their combinations.

Nano medicinal chemistry and quantitative structure-activity relationship (QSAR): Our laboratory has developed a list of biologically functional nano design features that could successfully improve the utility of the nano delivery systems by surface ligation andmodification, surface charge variation, size and aspect ratio tuning, controlling pore opening with nanovalves, use of imaging probes, etc. This has allowed us to summarize nano-QSAR for iterative particle optimization. It also positively impacts chemistry, manufacturing, and controls of nanotherapeutics (nano-CMC), facilitating the scale-up synthesis of nanotherapy. 

Nano/Bio interface and biological barriers: Biological systems have developed multi-tiered defense system to block foreign substances such as engineered nanomaterials from causing damage. In a pathological scenario, the disease itself may also pose additional barriers due to the imbalance between abnormal cells and their surrounding microenvironment, and NMs could behave similarly or differently to classic foreign substances, depending on their unique characteristics. We have looked into these complicated processes at nano/bio interface with great depth. We also use the discovery at nano/bio interface to improve the performance of nanotherapy.

Safety assessment of nanomedicine: The rate of translational effort of nanomedicine requires strategic planning of nanosafety research to be able to enable clinical trials and the safe use of nanomedicine in patients. Our lab addresses the challenges of safety assessment of nanomedicine, which is more dynamic and sophisticated than molecule based regimen.